X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs DIVIS LABORATORIES - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA DIVIS LABORATORIES ASTRAZENECA PHARMA/
DIVIS LABORATORIES
 
P/E (TTM) x 87.7 31.9 274.9% View Chart
P/BV x 19.3 7.2 269.1% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 ASTRAZENECA PHARMA   DIVIS LABORATORIES
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
DIVIS LABORATORIES
Mar-18
ASTRAZENECA PHARMA/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1,2781,142 111.9%   
Low Rs883533 165.6%   
Sales per share (Unadj.) Rs228.4146.6 155.8%  
Earnings per share (Unadj.) Rs10.433.0 31.4%  
Cash flow per share (Unadj.) Rs16.338.4 42.3%  
Dividends per share (Unadj.) Rs010.00 0.0%  
Dividend yield (eoy) %01.2 0.0%  
Book value per share (Unadj.) Rs98.8222.8 44.3%  
Shares outstanding (eoy) m25.00265.47 9.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.75.7 82.8%   
Avg P/E ratio x104.225.3 411.2%  
P/CF ratio (eoy) x66.421.8 304.7%  
Price / Book Value ratio x10.93.8 291.0%  
Dividend payout %030.3 0.0%   
Avg Mkt Cap Rs m27,008222,318 12.1%   
No. of employees `0001.410.8 12.6%   
Total wages/salary Rs m1,5354,561 33.7%   
Avg. sales/employee Rs Th4,210.93,616.0 116.5%   
Avg. wages/employee Rs Th1,132.2423.8 267.2%   
Avg. net profit/employee Rs Th191.1814.9 23.4%   
INCOME DATA
Net Sales Rs m5,71038,915 14.7%  
Other income Rs m1231,134 10.8%   
Total revenues Rs m5,83340,049 14.6%   
Gross profit Rs m46312,617 3.7%  
Depreciation Rs m1471,425 10.3%   
Interest Rs m013 0.0%   
Profit before tax Rs m43812,313 3.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1793,543 5.0%   
Profit after tax Rs m2598,770 3.0%  
Gross profit margin %8.132.4 25.0%  
Effective tax rate %40.828.8 141.9%   
Net profit margin %4.522.5 20.1%  
BALANCE SHEET DATA
Current assets Rs m3,20945,351 7.1%   
Current liabilities Rs m2,0706,507 31.8%   
Net working cap to sales %20.099.8 20.0%  
Current ratio x1.67.0 22.3%  
Inventory Days Days72127 57.1%  
Debtors Days Days3595 36.7%  
Net fixed assets Rs m79021,160 3.7%   
Share capital Rs m50531 9.4%   
"Free" reserves Rs m2,41958,625 4.1%   
Net worth Rs m2,46959,156 4.2%   
Long term debt Rs m00-   
Total assets Rs m4,60567,832 6.8%  
Interest coverage xNM926.8-  
Debt to equity ratio x00-  
Sales to assets ratio x1.20.6 216.1%   
Return on assets %5.612.9 43.4%  
Return on equity %10.514.8 70.8%  
Return on capital %17.720.8 85.1%  
Exports to sales %00-   
Imports to sales %021.8 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA8,485 0.0%   
Fx inflow Rs m30032,359 0.9%   
Fx outflow Rs m2,0159,042 22.3%   
Net fx Rs m-1,71523,317 -7.4%   
CASH FLOW
From Operations Rs m887,759 1.1%  
From Investments Rs m-94-4,783 2.0%  
From Financial Activity Rs mNA-3,142 0.0%  
Net Cashflow Rs m-6-166 3.4%  

Share Holding

Indian Promoters % 0.0 52.0 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 11.8 2.5%  
FIIs % 15.7 19.0 82.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 17.2 52.9%  
Shareholders   12,856 31,796 40.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   PLETHICO PHARMA  BIOCON   FULFORD INDIA  ALKEM LABORATORIES  ELDER PHARMA  

Compare ASTRAZENECA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End on a Strong Note; Sensex Ends 489 Points Higher(Closing)

After opening the day marginally lower, Indian share markets witnessed most of the buying interest during closing hours and ended their trading session on a strong note.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY19); Net Profit Up 10.6% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 10.6% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Mar 29, 2019 | Updated on Mar 29, 2019

Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 381.0% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 291 m (up 381.0% YoY). Sales on the other hand came in at Rs 2 bn (up 67.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (3QFY19); Net Profit Up 68.9% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 68.9% YoY). Sales on the other hand came in at Rs 13 bn (up 29.4% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

More Views on News

Most Popular

7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)

Jun 13, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

The Great Indian NBFC Bubble Has Burst but I Will Still Recommend These Safe NBFCs(The 5 Minute Wrapup)

Jun 11, 2019

One chart that predicted the NBFC crisis back in 2016.

Kenneth Andrade Would Like Our Real Estate Stock Recommendation with Triple Digit Upside(The 5 Minute Wrapup)

Jun 12, 2019

This real estate stock recommended in Smart Money Secrets offers the most favourable upside potential.

Why Modi 2.0 Will Be Great for These 7 Stocks(Profit Hunter)

Jun 10, 2019

The government's focus on Infra, electricity, water for all will be the key factors for Sensex 1,00,000.

Why I Believe Smallcaps Will Catch up to the Sensex(Profit Hunter)

Jun 14, 2019

Smallcaps have gone nowhere even as the Sensex makes new all-time highs. Find out why Richa believes this a good opportunity to invest in smallcaps.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Jun 20, 2019 03:35 PM

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 5-YR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS